Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Comprehensive Cancer Center, St Jude Children's Research Hospital, Memphis, TN, USA.
Nat Rev Cancer. 2024 Jun;24(6):382-398. doi: 10.1038/s41568-024-00684-9. Epub 2024 May 2.
In the past two decades, technological advances have brought unprecedented insights into the paediatric cancer genome revealing characteristics distinct from those of adult cancer. Originating from developing tissues, paediatric cancers generally have low mutation burden and are driven by variants that disrupt the transcriptional activity, chromatin state, non-coding cis-regulatory regions and other biological functions. Within each tumour, there are multiple populations of cells with varying states, and the lineages of some can be tracked to their fetal origins. Genome-wide genetic screening has identified vulnerabilities associated with both the cell of origin and transcription deregulation in paediatric cancer, which have become a valuable resource for designing new therapeutic approaches including those for small molecules, immunotherapy and targeted protein degradation. In this Review, we present recent findings on these facets of paediatric cancer from a pan-cancer perspective and provide an outlook on future investigations.
在过去的二十年中,技术的进步使我们对儿科癌症基因组有了前所未有的深入了解,揭示了其与成人癌症不同的特征。起源于发育中的组织,儿科癌症通常突变负担较低,由破坏转录活性、染色质状态、非编码顺式调控区域和其他生物学功能的变异驱动。在每个肿瘤中,都有多个具有不同状态的细胞群体,其中一些谱系可以追溯到其胎儿起源。全基因组遗传筛选已经确定了与儿科癌症起源细胞和转录失调相关的脆弱性,这些脆弱性已成为设计新治疗方法的宝贵资源,包括小分子治疗、免疫治疗和靶向蛋白降解等方法。在这篇综述中,我们从泛癌症的角度介绍了儿科癌症在这些方面的最新发现,并对未来的研究进行了展望。